References
- Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, . A phase 2 study of bortezomib in relapsed refractory myeloma. N Engl J Med 2003; 348:2609–2617.
- Rosiñol L, Montoto S, Cibeira MT, Bladé J. Bortezomib-induced severe hepatitis in multiple myeloma. Arch Intern Med 2005; 165: 464–465.
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:239–245.
- Edwards IR, Aronson JK. Adverse drug reactions. Lancet 2000; 356: 1255–1259.
- Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J, Mateos MV, . Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011; 118:4519–4529.